Biogen and AbbVie have been granted EU marketing authorization for Zinbryta (daclizumab), to treat adult patients with relapsing forms of multiple sclerosis. Relapse frequency per year was shown to be reduced by up to 45% against other treatments, and 54% against placebo.
Biogen is trying to emphasise the need for choice of treatments for MS, as the disease can vary widely in symptom manifestation and management from patient to patient. And this is where Zinbryta is particularly suited; to treat patients for whom 2 or more other therapies do not work so well.
Zinbryta is an antibody which selectively binds to the high-affinity interleukin-2 (IL-2) receptor subunit CD25. This is expressed at high levels on T-cells that become activated in people with MS.
It works to reduce immune modulation (and therefore inflammation of neurons) without actually depressing the immune system overall. The EC approval of Zinbryta is supported by results from two studies, including DECIDE, the largest and longest head-to-head Phase III study ever conducted in MS.